Ilaria Minato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilaria Minato has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Curti
Department of Food and Drug University of Parma Parma Italy
2 shared publications - Alessandra Bordoni
Department of Agri-Food Sciences and Technologies (DISTAL), University of Bologna, Piazza Goidanich 60, 47521 Cesena, Italy
1 shared publication - Alessandra Dei Cas
Department of Endocrinology and Metabolic Diseases, Parma University Hospital, 43126 Parma, Italy
1 shared publication - Alice Rosi
Human Nutrition Unit, Department of Food and Drug, University of Parma, 43125 Parma, Italy
1 shared publication - Andrea Belluzzi
Department of Medical and Surgical Sciences, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
1 shared publication - Barbara Montanini
Laboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy
1 shared publication
Latest Publications
- Open Access
- 21 April 2025
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 69 (15) , e70067
Evidence for a Modulatory Effect of a 12‐Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof‐of‐Principle Study
This study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with inflammatory bowel disease (IBD) in clinical remission. In this randomized, placebo‐controlled trial, 16 subjects with IBD in remission consumed POMJ or placebo for 12 weeks. POMJ consumption significantly reduced fecal calprotectin (FC) and plasma endotoxin levels. Transcriptomic analysis of peripheral blood mononuclear cells revealed upregulation of genes involved in mucosal immunity, including aryl hydrocarbon receptor ( AHR ), neutrophil cytosolic factor 4 ( NCF4 ), and nuclear factor, interleukin 3 regulated ( NFIL3 ). Urolithin metabotypes were predominantly of the B type, associated with intestinal dysbiosis. No significant changes were observed in serum inflammatory markers or colonic mucosal cytokine expression. POMJ consumption reduced markers of intestinal inflammation and modulated gene expression related to mucosal immunity and barrier function in patients with IBD. These findings suggest the potential of POMJ as a beneficial dietary intervention for maintaining remission in IBD, highlighting the promise of targeted nutritional strategies in managing chronic inflammatory conditions. Further research is needed to elucidate the long‐term clinical implications of these molecular changes. Trial Registration: ClinicalTrials.gov identifier: NCT03000101 .
- 21 April 2025
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 69 (15) , e70067
Open AccessEvidence for a Modulatory Effect of a 12‐Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof‐of‐Principle Study
This study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with inflammatory bowel disease (IBD) in clinical remission. In this randomized, placebo‐controlled trial, 16 subjects with IBD in remission consumed POMJ or placebo for 12 weeks. POMJ consumption significantly reduced fecal calprotectin (FC) and plasma endotoxin levels. Transcriptomic analysis of peripheral blood mononuclear cells revealed upregulation of genes involved in mucosal immunity, including aryl hydrocarbon receptor ( AHR ), neutrophil cytosolic factor 4 ( NCF4 ), and nuclear factor, interleukin 3 regulated ( NFIL3 ). Urolithin metabotypes were predominantly of the B type, associated with intestinal dysbiosis. No significant changes were observed in serum inflammatory markers or colonic mucosal cytokine expression. POMJ consumption reduced markers of intestinal inflammation and modulated gene expression related to mucosal immunity and barrier function in patients with IBD. These findings suggest the potential of POMJ as a beneficial dietary intervention for maintaining remission in IBD, highlighting the promise of targeted nutritional strategies in managing chronic inflammatory conditions. Further research is needed to elucidate the long‐term clinical implications of these molecular changes. Trial Registration: ClinicalTrials.gov identifier: NCT03000101 .
- Open Access
- 29 January 2020
- Published by MDPI AG in Nanomaterials
- Vol. 10 (2) , 235
Cerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson’s Disease
Over the last decades, cerium oxide nanoparticles (CeO2 NPs) have gained great interest due to their potential applications, mainly in the fields of agriculture and biomedicine. Promising effects of CeO2 NPs are recently shown in some neurodegenerative diseases, but the mechanism of action of these NPs in Parkinson’s disease (PD) remains to be investigated. This issue is addressed in the present study by using a yeast model based on the heterologous expression of the human α-synuclein (α-syn), the major component of Lewy bodies, which represent a neuropathological hallmark of PD. We observed that CeO2 NPs strongly reduce α-syn-induced toxicity in a dose-dependent manner. This effect is associated with the inhibition of cytoplasmic α-syn foci accumulation, resulting in plasma membrane localization of α-syn after NP treatment. Moreover, CeO2 NPs counteract the α-syn-induced mitochondrial dysfunction and decrease reactive oxygen species (ROS) production in yeast cells. In vitro binding assay using cell lysates showed that α-syn is adsorbed on the surface of CeO2 NPs, suggesting that these NPs may act as a strong inhibitor of α-syn toxicity not only acting as a radical scavenger, but through a direct interaction with α-syn in vivo.
- 29 January 2020
- Published by MDPI AG in Nanomaterials
- Vol. 10 (2) , 235
Open AccessCerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson’s Disease
Over the last decades, cerium oxide nanoparticles (CeO2 NPs) have gained great interest due to their potential applications, mainly in the fields of agriculture and biomedicine. Promising effects of CeO2 NPs are recently shown in some neurodegenerative diseases, but the mechanism of action of these NPs in Parkinson’s disease (PD) remains to be investigated. This issue is addressed in the present study by using a yeast model based on the heterologous expression of the human α-synuclein (α-syn), the major component of Lewy bodies, which represent a neuropathological hallmark of PD. We observed that CeO2 NPs strongly reduce α-syn-induced toxicity in a dose-dependent manner. This effect is associated with the inhibition of cytoplasmic α-syn foci accumulation, resulting in plasma membrane localization of α-syn after NP treatment. Moreover, CeO2 NPs counteract the α-syn-induced mitochondrial dysfunction and decrease reactive oxygen species (ROS) production in yeast cells. In vitro binding assay using cell lysates showed that α-syn is adsorbed on the surface of CeO2 NPs, suggesting that these NPs may act as a strong inhibitor of α-syn toxicity not only acting as a radical scavenger, but through a direct interaction with α-syn in vivo.
- 8 January 2020
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 64 (5) , e1900890
Flavonoid‐Derived Human Phenyl‐γ‐Valerolactone Metabolites Selectively Detoxify Amyloid‐β Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease
Scope: Amyloid‐β oligomers (AβO) are causally related to Alzheimer's disease (AD). Dietary natural compounds, especially flavonoids and flavan‐3‐ols, hold great promise as potential AD‐preventive agents but their host and gut microbiota metabolism complicates identification of the most relevant bioactive species. This study aims to investigate the ability of a comprehensive set of phenyl‐γ‐valerolactones (PVL), the main circulating metabolites of flavan‐3‐ols and related dietary compounds in humans, to prevent AβO‐mediated toxicity.Methods and results: The anti‐AβO activity of PVLs is examined in different cell model systems using a highly toxic β‐oligomer‐forming polypeptide (β23) as target toxicant. Multiple PVLs, and particularly the monohydroxylated 5‐(4′‐hydroxyphenyl)‐γ‐valerolactone metabolite [(4′‐OH)‐PVL], relieve β‐oligomer‐induced cytotoxicity in yeast and mammalian cells. As revealed by atomic force microscopy (AFM) and other in vitro assays, (4′‐OH)‐PVL interferes with AβO (but not fibril) assembly and actively remodels preformed AβOs into nontoxic amorphous aggregates. In keeping with the latter mode of action, treatment of AβOs with (4′‐OH)‐PVL prior to brain injection strongly reduces memory deterioration as well as neuroinflammation in a mouse model of AβO‐induced memory impairment.Conclusion: PVLs, which have been validated as biomarkers of the dietary intake of flavan‐3‐ols, lend themselves as novel AβO‐selective, candidate AD‐preventing compounds.
- 8 January 2020
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 64 (5) , e1900890
Flavonoid‐Derived Human Phenyl‐γ‐Valerolactone Metabolites Selectively Detoxify Amyloid‐β Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease
Scope: Amyloid‐β oligomers (AβO) are causally related to Alzheimer's disease (AD). Dietary natural compounds, especially flavonoids and flavan‐3‐ols, hold great promise as potential AD‐preventive agents but their host and gut microbiota metabolism complicates identification of the most relevant bioactive species. This study aims to investigate the ability of a comprehensive set of phenyl‐γ‐valerolactones (PVL), the main circulating metabolites of flavan‐3‐ols and related dietary compounds in humans, to prevent AβO‐mediated toxicity.Methods and results: The anti‐AβO activity of PVLs is examined in different cell model systems using a highly toxic β‐oligomer‐forming polypeptide (β23) as target toxicant. Multiple PVLs, and particularly the monohydroxylated 5‐(4′‐hydroxyphenyl)‐γ‐valerolactone metabolite [(4′‐OH)‐PVL], relieve β‐oligomer‐induced cytotoxicity in yeast and mammalian cells. As revealed by atomic force microscopy (AFM) and other in vitro assays, (4′‐OH)‐PVL interferes with AβO (but not fibril) assembly and actively remodels preformed AβOs into nontoxic amorphous aggregates. In keeping with the latter mode of action, treatment of AβOs with (4′‐OH)‐PVL prior to brain injection strongly reduces memory deterioration as well as neuroinflammation in a mouse model of AβO‐induced memory impairment.Conclusion: PVLs, which have been validated as biomarkers of the dietary intake of flavan‐3‐ols, lend themselves as novel AβO‐selective, candidate AD‐preventing compounds.